IJFANS INTERNATIONAL JOURNAL OF FOOD AND NUTRITIONAL SCIENCES
ISSN PRINT 2319 1775 Online 2320 7876

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11,Nov 2022

Information Current for General Practitioners Regarding Oral Fungal Infections

Dr. Puneet Kumar[1], Dr. Chandni Batra[2*]

[1]Professor, Department of Public Health Dentistry, Santosh Dental College & Hospital, Santosh Deemed to be University, Ghaziabad.
[2*]Reader, Department of Oral Medicine, Diagnosis & Radiology, Santosh Dental College & Hospital, Santosh Deemed to be University, Ghaziabad.

Corresponding Author: [2]*Dr. Chandni Batra

ABSTRACT
Background:
The most typical fungus infection seen in routine dental care is oral candidosis. It can show clinically in a number of ways that may resemble more serious illnesses, and it can occasionally be resistant to therapy, necessitating the care of an expert in oral medicine. Since oral candidosis frequently manifests in patients who have impaired immune systems, treatment of the ailment should always entail a thorough investigation of underlying risk factors. The pathophysiology, clinical presentation, and therapy approaches of oral Candidal lesions frequently seen in dental practise are highlighted in this update.

Keywords: Dental Practise, Candidal Lesions, Typical Fungi, Oral Candidosis.

1. INTRODUCTION

The number of immunocompromised people in the community has dramatically increased as a result of rising diabetes rates, longer life expectancies, the use of broad-spectrum antibiotics and immunosuppressive medication, and the appearance of the human immunodeficiency virus. A variety of opportunistic infections coexist with these immunological dysregulations, with oral candidosis being the most clinically significant for dental health practitioners. The pathophysiology, clinical presentation, and therapy approaches of oral Candidal lesions frequently seen in dental practise are highlighted in this study.

Aetiology and pathogenesis
Commensal Candida species are the cause of oropharyngeal candidosis. Even while the vast majority of healthy people have intraoral Candida strains, only certain people get oral candidosis.Over 80% of lesions include an isolated strain of Candida albicans, which is the most often implicated strain.[1,2]C. tropicalis, C. glabrata, C. parapsilosis, C. stellatoidea, C. krusei, C. kefyr, and more recently, C. dubliniensis in immunocompromised people, are less frequent strains.[3,4]
The most prevalent species of Candida isolated from the oral cavity in both health and disease is Candida albicans. [5] A higher incidence was identified in healthy children and young adults, with reported prevalence in clinically normal mouths ranged from 3 to 48%7.

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11,Nov 2022

[6,7] Additionally, hospitalised patients have increased candidal carriage. [8,9] This is significant because the isolation of Candida from the oral cavity alone cannot be utilised to establish a diagnosis; rather, it must be used in concert with other clinical indications and symptoms.In addition to virulence characteristics ascribed to the organism itself, predisposing conditions are frequently linked to the transformation of Candida from a commensal to a pathogen.[10] The most important ones are covered below.

Those that predispose

Drug treatment

Oral candidosis is exacerbated by a number of pharmacologic agent classes. [11, 12] These include xerogenic medicines, immunomodulatory medications, and broad-spectrum antibiotics. Broad-spectrum antibiotic use may put patients at risk for changes to their commensal oral microbiota. Candida levels are regulated in healthy individuals by oral microbiota through competition for food substrates and epithelial cell adhesion. [10] Changes in the commensal microbiota could lead to unchecked Candidal overgrowth. Through their immunomodulatory actions, the systemic side effects of broad-spectrum antibiotic therapy may potentially contribute to oral candidosis. [10]

Prescription medications frequently cause xerostomic adverse effects. Antidepressants, antipsychotics, anticholinergics, antihypertensives, and antiadrenergics are those that are most frequently implicated. [13] The oral health issues brought on by objective hypofunction of the salivary glands, including oral candidosis, are of clinical importance. Increased commensal Candidal levels in these patients may be explained by the concurrent reductions in salivary flushing action and antifungal salivary ingredients (lactoferrin, lysozyme, histatins, and immunoglobulins). [14]

Malignancy and blood dyscrasias

When solid organ or haematological cancers are treated with cytotoxic chemotherapy or radiation therapy, the host's natural defences are weakened, and oral candidosis usually develops as a result. [15,16] Between 30 to 94% of patients in this patient group have been documented to have oral candidiasis. [17] Such lesions are primarily characterised by mucosal injury and protracted neutropenia during their progression. [17]

Dietary variables

The genesis of oral candidal infections has been linked to a number of dietary variables. Reduced host defences and a loss of mucosal integrity may be caused by protein-energy malnutrition, iron, folate, vitamin C, vitamin B12, and maybe vitamin A24 deficiency. These conditions also increase the risk of hyphal invasion and infection. [12] On the other hand, diets high in carbohydrates might be a risk factor that makes it more likely that Candida species will adhere to epithelial cells.[19]

Endocrine issues

Comparable studies by Manfredi et al.[17] and Al-Karaawi et al.[4] present contradictory findings with lower rates of candidal carriage in diabetic patients compared with healthy controls, in contrast to some studies that have shown an increased prevalence of Candida in the oral cavity of diabetic subjects. Poorly managed patients have the highest rates of colonisation, suggesting that the degree of glycaemic control may be more important than the existence of the disease itself. [20] Diabetes problems include decreased salivary flow,

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11,Nov 2022

decreased pH, and elevated salivary glucose levels, which are known to promote oral Candidal growth and colonisation, are amplified by poor control. [16]
Therefore, people with diabetes have a higher risk of developing oral Candida infections than do patients without diabetes. Studies on animals reveal that there is a propensity to disease and that diabetics are more susceptible to oral candidosis. [3]

Disordered immune systems
A recurrent symptom of numerous immune deficiencies is oral candidosis. [5] The immune system's humoral and cell-mediated components both help to prevent and get rid of fungal infections in the oral and perioral areas. An individual's susceptibility to such infections is increased by impaired or reduced immune function.
People receiving dual antiviral medication see fewer outbreaks. [14] While HIV may impact a variety of cell types, it is most likely that progressive CD4+ T lymphocyte depletion is what makes these patients more vulnerable to opportunistic infections. [5] In addition, a number of additional immunodeficiencies, such as Chediak-Higashi syndrome, DiGeorge syndrome, hereditary myeloperoxidase deficiency, and severe combined immunodeficiency syndrome, usually show as candidosis. [5]

Salivary changes
As was already noted, saliva is crucial in preventing Candidal overgrowth. One of the main risk factors for oral candidosis in people is abnormalities in their normal salivary physiology. [16]Oral Candida is more prevalent when there is hyposalivation and a decrease in salivary pH.[17] Caffeine and ethanol both lower salivary flow and may contribute to the aetiology of oral candidosis.Regardless of oral hygiene practises and wearing dentures, people with primary and secondary Sjogren's disease had a greater frequency of oral yeast carriage.[16]
Patients with HIV and persistent hepatitis C virus infection may develop oral candidosis and salivary gland hypofunction as a result of lymphocytic sialadenitis. [18] Sialadenosis can lead to xerostomia and increase the risk of candidosis in people who are alcoholics, diabetics, and people with other metabolic problems. [19]Finally, a higher level of oral Candida carriage has been linked to smoking.[20]It is still unclear whether this is brought on by altered salivary function, altered epithelial function, or increased Candida development. [21]

Presenting a clinical case
There are many different clinical symptoms of oral candidosis, and it can infect one or more mucosal surfaces.

Pseudomembranous candidosis It is possible to remove the lesion's outer layer of whiteness to disclose an erythematous surface that may slightly bleed. [2] Lesions typically show no symptoms. [2] The plaques are made up of fibrin, desquamated epithelial cells, necrotic debris, and fungi hyphae. [12] Most healthy people histologically exhibit hyphal invasion up to the stratum spinosum. It has been established that in immunocompromised patients, hyphal extension beyond the spinous layer occurs. [2] Microabscesses occur inside the epithelium as a result of focal aggregation of polymorphonuclear leukocytes (PMNL). Immunocompromised people have a decreased level of this trait. [2] A lymphocytic infiltration is visible in the surrounding connective tissue, and acanthosis is visible in the epithelium's deeper layers. [5]

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11,Nov 2022

Hyperplastic candidosis The post-commissural buccal mucosa, the tongue, and the palate posterior to upper dentures are the three areas where these lesions are most frequently found. [22,23] It is crucial to recognise these lesions since they have been linked to more dysplasia and cancer than leukoplakia without a Candidal connection. [22] It is yet unknown if Candida plays a causal or a preventative role in the development of oral cancer. Additionally, it is possible that the initial pathosis of oral cancer may be dysplastic or malignant and have acquired secondary Candida infection. [24]

Erythematous candidosis It usually develops on the palate and dorsum of the tongue, and less frequently on the buccal mucosa. [2] The persistent use of broad-spectrum antibiotics[10] and corticosteroids is linked to this variation, formerly known as antibiotic sore mouth. [11] Patients with HIV infections also have it. [16] This lesion resembles pseudomembranous candidosishistopathologically. [5]

Angular cheilitis Clinically, it manifests as erythematous, fissured lesions that affect the mouth's angles. [2] It is frequently bilateral and symptomatic. [2] The labial commissures and nasolabial creases on the face may accumulate saliva and create a persistently moist environment that is a risk factor for angular cheilitis. Patients who wear dentures and have a smaller vertical occlusal dimension frequently exhibit this. [25] Although nutritional variables play a significant aetiologic role in the development of these lesions, it is presently believed that the majority of these lesions are brought on by Candida species, Staphylococcus, or Streptococci. [5]

Chronic mucocutaneouscandidosisA diverse illness called chronic mucocutaneouscandidosis is characterised by recurring or persistent Candidal infection of the mucosa, nails, and skin. [15] All of these patients had oral candidosis in more than 90% of cases. [5] It frequently occurs in conjunction with a number of endocrinopathies and immunodeficiencies. [5]

Medical differential diagnosis

It is important to distinguish between candida infections and other lesions with comparable clinical manifestations. Differentiation from other lesions with a pseudomembrane is crucial in pseudomembranous variations. These include syphilis, traumatic lesions, chemical burns, traumatic lesions, and various white keratotic lesions. [5] It is important to distinguish between thermal traumatic lesions, erosive lichen planus and lichenoid reactions, lupus erythematosis, erythema multiforme, pernicious anaemia, and epithelial dysplasia from solitary erythematous lesions such erythematous candidosis (acute and chronic variants).

In-lab examinations

Oral candidosis is often diagnosed with a comprehensive medical history together with clinical signs and symptoms. Clinical specimens are sent to additional laboratory testing in order to confirm preliminary findings. There are several techniques for testing the oral mucosa for the presence of Candida. [26]

These techniques include swabs, impression cultures, entire saliva collections, mouth rinse samples, and incisional biopsies. [27] Each sample methodology has specific benefits and drawbacks, and the technique to use depends on the type of lesion being studied.

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11,Nov 2022

In refractory lesions or in people who have compromised immune systems, it may be necessary to differentiate between different Candida strains. Although some media can distinguish between a number of species based on macroscopic colony characteristics [28], immunohistochemical procedures are necessary for comprehensive distinction between various strains of Candida. [5] Antifungal sensitivity testing, in addition to strain identification, may be helpful in resistant lesions to ascertain susceptibility and to guide definitive antifungal therapy.

Management

The onset of candidosis is uncommon in the absence of risk factors.Therefore, through a thorough history taking, care should be focused on identifying and addressing, if feasible, any underlying conditions that may predispose or contribute to oral candidosis. [5,12,29] Iron, folate, vitamins B12 and C, as well as diabetes mellitus and other immunodeficiencies, should all be eliminated. Any pharmacologic substances that might be involved should be found and, if possible, replaced with an alternate medication.

To determine salivary gland function and hydration, saliva tests should be done.Drug therapy is required if correcting the underlying issues is neither possible nor recommended. The majority of the time, topical polyene or azole antifungal medicines are successful. The patient's medical history, mouth symptoms, and expected compliance with application method are only a few of the many variables that influence the drug selection process. Following are a few prevalent regimes.

A different or additional antifungal agent can be required in recalcitrant lesions. Referral to an oral medicine specialist and treatment with systemic antifungal medications (ketoconazole, fluconazole, and itraconazole, and sometimes in individuals with azole-resistant strains, amphotericin) may be judged required if the course of treatment is still unsuccessful.

2. REFERENCES

1. McCullough MJ, Clemons KV, Stevens DA. Molecular epidemiology of the global and temporal diversity of Candida albicans.Clin Infect Dis 1999;29:1220–1225.
2. Reichart PA, Samaranayake LP, Philipsen HP. Pathology andclinical correlates in oral candidiasis and its variants: a review.Oral Dis 2000;6:85–91.
3. McCullough MJ, Ross BC, Reade PC. Candida albicans: a reviewof its history, taxonomy, epidemiology, virulence attributes, andmethods of strain differentiation. Int J Oral MaxillofacSurg1996;25:136–144.
4. Al-Karaawi ZM, Manfredi M, Waugh AC, et al. Moleculcharacterization of Candida spp. isolated from the oral cavities ofpatients from diverse clinical settings. Oral MicrobiolImmunol2002;17:44–49.
5. Farah CS, Ashman RB, Challacombe SJ. Oral candidosis. ClinDermatol 2000;18:553–562.
6. MacFarlane TW, Samaranayake LP. Oral candidosis. London:Wright, 1990.
7. Arendorf TM, Walker DM. The prevalence and intra-oral distribution of Candida albicans in man. Arch Oral Biol 1980;25:1–10.
8. Qi QG, Hu T, Zhou XD. Frequency, species and molecularcharacterization of oral Candida in hosts of different age inChina. J Oral Pathol Med 2005;34:352–356.
9. Odds FC. Pathogenesis of Candida infections. J Am Acad Dermatol 1994;31:S2–S5.

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 11,Nov 2022

10. Soysa NS, Samaranayake LP, Ellepola AN. Antimicrobials as acontributory factor in oral candidosis-a brief overview. Oral Dis2008;14:138–143.
11. Ellepola ANB, Samaranayake LP. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis 2001;7:211–216.
12. Sherman RG, Prusinski L, Ravenel MC, Joralmon RA. Oralcandidosis. Quintessence Int 2002;33:521–532.
13. Ellepola AN, Samaranayake LP. Inhalational and topical steroids,and oral candidosis: a mini review. Oral Dis 2001;7:211–216.
14. Baid SK, Nieman LK. Therapeutic doses of glucocorticoids:implications for oral medicine. Oral Dis 2006;12:436–442.
15. MIMS Annual. Crows Nest, New South Wales, 2009.
16. Scully C. Drug effects on salivary glands: dry mouth. Oral Dis2003;9:165–176.
17. Leung KC, McMillan AS, Cheung BP, Leung WK. Sjo¨ gren'ssyndrome sufferers have increased oral yeast levels despite regulardental care. Oral Dis 2008;14:163–173.
18. Clarkson JE, Worthington HV, Eden OB. Interventions for preventing oral candidiasis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews (Online)2007;CD003807.
19. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-labelrandomized trial comparing itraconazole oral solution withfluconazole oral solution for primary prophylaxis of fungalinfections in patients with haematological malignancy andprofound neutropenia. J AntimicrobChemother 2006;57:317–325.
20. Chaushu G, Bercovici M, Dori S, et al. Salivary flow and itsrelation with oral symptoms in terminally ill patients. Cancer2000;88:984–987.
21. Davies AN, Brailsford SR, Beighton D. Oral candidosis in patients with advanced cancer. Oral Oncol 2006;42:698–702.
22. Belazi M, Velegraki A, Koussidou-Eremondi T, et al. Oral Candida isolates in patients undergoing radiotherapy for head andneck cancer: prevalence, azole susceptibility profiles and responseto antifungal treatment. Oral MicrobiolImmunol 2004;19:347–351.
23. De Pauw BE. Practical modalities for prevention of fungalinfections in cancer patients. Eur J ClinMicrobiol Infect Dis1997;16:32–41.
24. Montes LF, Krumdieck C, Cornwell PE. Hypovitaminosis A inpatients with mucocutaneous candidiasis. J Infect Dis1973;128:227–230.
25. Samaranayake L, MacFarlane T. On the role of dietary carbohydrates in the pathogenesis of oral candidosis. FEMS Microbiology Letters 1985;27.
26. McCarthy GM, Mackie ID, Koval J, Sandhu HS, Daley TD.Factors associated with increased frequency of HIV-related oralcandidiasis. J Oral Pathol Med 1991;20:332–336.
27. Oral candidosis in HIV infection. Lancet 1989;2:1491–1492.
28. Umadevi KMR, Ranganathan K, Pavithra S, et al. Oral lesionsamong persons with HIV disease with and without highly activeantiretroviral therapy in southern India. J Oral Pathol Med2007;36:136–141.
29. Nielsen H, Bentsen KD, Hojtved L, et al. Oral candidiasis andimmune status of HIV-infected patients. J Oral Pathol Med1994;23:140–143.